유럽 연합 - 독일어 - EMA (European Medicines Agency)

novartis europharm limited - nateglinid - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - nateglinid ist indiziert für die kombinationstherapie mit metformin bei typ-2-diabetikern, die trotz einer maximal tolerierten dosis von metformin allein nicht ausreichend kontrolliert werden.

유럽 연합 - 독일어 - EMA (European Medicines Agency)

novartis europharm ltd. - nateglinid - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - nateglinid ist indiziert für die kombinationstherapie mit metformin bei typ-2-diabetikern, die trotz einer maximal tolerierten metformindosis allein nicht ausreichend kontrolliert werden.

유럽 연합 - 독일어 - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecyclin - bacterial infections; skin diseases, bacterial; soft tissue infections - antibiotika für den systemischen einsatz, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. es sollte erwogen werden, um die offiziellen richtlinien über den angemessenen gebrauch von antibakteriellen wirkstoffen. angemessenen gebrauch von antibakteriellen wirkstoffen.

유럽 연합 - 독일어 - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmika - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

유럽 연합 - 독일어 - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmika - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - glibenclamidum - tabletten - glibenclamidum 5 mg, lactosum 79 mg, maydis amylum, talcum, silica colloidalis anhydrica, magnesii stearas pro compresso. - antidiabetikum oral - synthetika

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - gliclazidum - tabletten mit veränderter wirkstofffreisetzung - gliclazidum 30 mg, excipiens pro compresso. - antidiabetikum oral - synthetika

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - gliclazidum - tabletten mit veränderter wirkstofffreisetzung - gliclazidum 60 mg, excipiens pro compresso. - antidiabetikum oral - synthetika

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - exenatidum - injektionslösung im fertigpen - exenatidum 5 µg, natrii acetas trihydricus corresp. natrium 5.4 µg, acidum aceticum glaciale, mannitolum, metacresolum, aqua ad iniectabile q.s. ad solutionem pro 20 µl corresp., exenatidum 0.25 mg/ml. - antidiabetikum - synthetika

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - exenatidum - injektionslösung im fertigpen - exenatidum 10 µg, natrii acetas trihydricus corresp. natrium 10.7 µg, acidum aceticum glaciale, mannitolum, metacresolum, aqua ad iniectabile q.s. ad solutionem pro 40 µl corresp., exenatidum 0.25 mg/ml. - antidiabetikum - synthetika